Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 30 X 100 mg |
|
||
|
Film Coated Tablets 30 X 150 mg |
|
Related information
Dosage
Non-small cell lung cancer: 150 mg daily without food. Treatment should continue until disease progression or unacceptable toxicity occurs. There is no evidence that treatment beyond progression is beneficial.
Pancreatic cancer: 100 mg daily without food, in combination with gemcitabine.
Please refer to license holder for full details.
Indications
Non-Small Cell Lung Cancer (NSCLC): Erlotinib is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations. Erlotinib is indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations and stable disease after first-line chemotherapy. Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.Pancreatic cancer: Erlotinib is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Contra-Indications
Hypersensitivity to erlotinib or to any of the excipients.
Special Precautions
Please refer to license holder for full details.
Side Effects
Please refer to license holder for full details.
Drug interactions
Please refer to license holder for full details.
Pregnancy and Lactation
Please refer to license holder for full details.
Overdose
Please refer to license holder for full details.
Important notes
Please refer to license holder for full details.
